Related Experiment Video
Updated: Dec 13, 2025

A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide
Published on: December 15, 2014
Useful Cases of Patients With Developmental Disorders Improved by Oral Administration of LPS Derived from Pantoea
Atsutomo Morishima1, Ran Zhang2,3, Takema Nagaoka2
1Lavita Integrative Medical Clinic, Osaka, Japan atsu5426@yahoo.co.jp.
Background:
Developmental disorders are associated with microglial dysfunction. Oral administration of lipopolysaccharide derived from Pantoea agglomerans bacteria (LPSp) leads to normalization of phagocytic activity of microglia and suppression of inflammation in mice. In this article, we report on a successful trial in which we achieved a significant improvement of symptoms in patients with developmental disorders.
Patients And Methods:
Five pediatric patients diagnosed with autism spectrum disorders (ASD)/attention deficit hyperactivity disorder (ADHD) who visited our clinic received either 0.75 or 1 mg/day LPSp for 6 months or more, in addition to our usual therapy regimens (detoxification therapy, nutritional therapy, and vibration therapy). A survey questionnaire was completed by the patients' parents and evaluated using the Numerical Rating Scale.
Results:
Behavior, verbal ability, and communication disabilities associated with ASD/ADHD improved in all patients.
Conclusion:
Oral administration of LPSp may represent a new treatment option in the area of developmental disorders where there is currently no treatment available.
Insights
Oral administration of Pantoea agglomerans lipopolysaccharide (LPSp) improved symptoms in children with developmental disorders. This suggests LPSp may be a novel therapeutic option for conditions like autism spectrum disorder and ADHD.
Area of Science:
- Neuroscience
- Immunology
- Microbiology
Background:
- Microglial dysfunction is linked to developmental disorders.
- Pantoea agglomerans lipopolysaccharide (LPSp) normalizes microglial phagocytosis and reduces inflammation in mice.
- This study investigates LPSp's efficacy in human patients.
Purpose of the Study:
- To evaluate the therapeutic potential of LPSp in pediatric patients with developmental disorders.
- To assess the impact of LPSp on symptoms associated with autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD).
Main Methods:
- A trial involving five pediatric patients diagnosed with ASD/ADHD.
- Patients received 0.75 or 1 mg/day of LPSp for at least six months, alongside standard therapies.
- Parental survey questionnaires were used for evaluation via the Numerical Rating Scale.
Main Results:
- All patients showed significant improvements in behavior, verbal ability, and communication.
- The study observed positive outcomes in core symptoms of ASD/ADHD.
Conclusions:
- Oral LPSp administration shows promise as a new treatment for developmental disorders.
- LPSp may offer a novel therapeutic avenue where current treatments are limited.
Related Concept Videos
Formation of Lipopolysaccharides
Lysosomal Hydrolases

